关节疼痛注射市场－全球产业规模、份额、趋势、机会、预测：按註射类型、应用、地区和竞争格局划分，2021-2031年

全球关节疼痛注射剂市场预计将从 2025 年的 47.2 亿美元成长到 2031 年的 73.9 亿美元，复合年增长率为 7.76%。

这些治疗方法包括将止痛药和抗发炎药物直接注射到关节腔，以缓解肌肉骨骼疼痛并改善活动能力。该领域的发展主要受全球人口老化和骨关节炎盛行率上升的驱动，从而导致对有效非手术治疗方法的需求日益增长。根据英国关节炎协会的数据，到2025年，英国将有超过1000万人患有关节炎，这凸显了对能够弥合口服药物和侵入性手术之间疗效差距的对症治疗方法的迫切需求。

然而，关节内注射皮质类固醇的长期安全性问题在市场中面临许多挑战。反覆注射此类药物会带来关节感染和软骨劣化等风险，这往往会阻碍其在临床上的持续应用。因此，医疗机构不得不限制用药频率，这对注射疗法领域的持续发展构成了重大挑战。

市场驱动因素

类风湿性关节炎和骨关节炎盛行率的上升是全球关节疼痛注射市场的主要驱动力。随着世界人口老化，退化性关节疾病的负担日益加重，对非手术缓解症状的需求也随之稳定成长。这种人口结构的变化迫使医疗保健系统优先考虑注射疗法，例如透明质酸和皮质类固醇，并推迟疼痛管理和全膝关节置换术术等侵入性手术。根据美国疾病管制与预防中心 (CDC) 于 2025 年 6 月发布的报告《预防慢性疾病》，美国 20 岁及以上成年人的关节炎粗略盛行率将达到 27.9%，这凸显了有效关节内治疗对于提高工作效率和生活品质的迫切需求。

此外，全球肥胖率的飙升正在推动市场扩张，因为它加速了关节退化，并降低了关节炎的平均发病年龄。超重会对负重关节造成严重的机械压力，加速软骨破坏，并需要更早治疗性介入。 2025年3月发布的《2025年世界肥胖地图集》预测，2030年，全球肥胖成年人口将达到11.3亿。这一趋势与肌肉骨骼合併症的增加密切相关，迫使製药公司扩大其疼痛管理产品组合。 ANICKA Therapeutics在2025年报告称，其2024年骨关节炎疼痛管理产品的国际收入年增了17%，这反映了上述趋势。

市场挑战

全球注射型关节疼痛市场成长的主要障碍在于长期使用关节内注射皮质类固醇的安全隐患。虽然这些药物能有效缓解暂时性疼痛，但由于软骨劣化和关节感染等风险，其持续使用受到限制。因此，医疗专业人员不得不限制治疗频率，通常会为患者设定年度用药次数上限。这种安全限制使得该疗法难以成为慢性疼痛管理的可持续解决方案，降低了每位患者的收入，并导致其市场渗透率低于可每日服用且无类似操作限制的口服镇痛药。

鑑于需要持续疼痛管理的患者群体庞大，这项限制尤为重要。根据美国疾病管制与预防中心（CDC）预测，到2025年，21.3%的美国成年人将被诊断出患有关节炎。虽然这数据凸显了寻求缓解疼痛的大规模人群，但无法安全、频繁地註射皮质类固醇却成为服务提供的一大瓶颈。疾病的高发生率与治疗方法频率的限制之间的差距，直接阻碍了市场充分利用对有效肌肉骨骼治疗方法的需求。

市场趋势

随着临床医生越来越重视组织修復而非暂时缓解症状，整形外科生物製剂和再生医学的日益普及正在重塑市场格局。这一趋势包括将富血小板血浆 (PRP) 和透明质酸支架等生物解决方案应用于临床，旨在修復受损软骨并延缓人工关节重建。医疗机构正迅速将这些治疗方法纳入治疗通讯协定，以解决关节退化的根本原因，而不仅仅是掩盖疼痛。 Anika Therapeutics 在 2025 年 11 月发布的 2025 年第三季财报中指出，其再生医学解决方案业务的营收成长了 25%。这主要得益于其完整性植入系统的市场成功以及 Hi-Alofast 在国际市场的持续拓展。

为了减轻临床负担并提高患者就医便利性，单次注射关节内粘稠补充疗法正在逐步推广。传统的多次注射疗程需要患者反覆就医，而单次注射高分子量透明质酸製剂只需一次给药即可提供持续的治疗效果。这种方法已成为膝骨关节炎治疗的首选方案，提高了医疗机构的运作效率并增强了患者的依从性。根据Bioventus公司2025年第三季财报，其疼痛管理领域的全球销售额成长了6.4%。这主要得益于美国市场对Durolaine（一种差异化的单次注射透明质酸疗法）的强劲需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球关节疼痛注射市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 注射类型（类固醇关节注射、玻尿酸注射、富血小板血浆（PRP）注射、胎盘组织基质（PTM）注射等）
  • 依应用部位（肩/肘、膝/踝、脊椎关节、髋关节、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美关节疼痛注射市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲关节疼痛注射市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区关节疼痛注射市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲关节疼痛注射市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美关节疼痛注射市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球关节疼痛注射市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Anika Therapeutics Inc
• Bioventus LLC
• Ferring Pharmaceuticals Inc
• Sanofi SA
• Pfizer Inc
• Eli Lilly & Co
• Flexion Therapeutics Inc
• Teva Pharmaceutical Industries Ltd
• Zimmer Biomet Holdings, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The global market for joint pain injections is projected to expand from USD 4.72 billion in 2025 to USD 7.39 billion by 2031, reflecting a compound annual growth rate of 7.76%. These therapeutic procedures involve the direct delivery of analgesic or anti-inflammatory medications into the synovial joint space to alleviate musculoskeletal pain and enhance mobility. The sector's growth is primarily fueled by the aging global population and the rising prevalence of osteoarthritis, which creates a strong need for effective non-surgical management options. Data from Arthritis UK indicates that over 10 million individuals in the United Kingdom were living with arthritis in 2025, highlighting the critical demand for symptomatic relief therapies that bridge the gap between oral pharmaceuticals and invasive surgeries.

However, the market encounters a significant obstacle regarding the safety profile of long-term intra-articular corticosteroid use. Repeated administration of these agents carries risks such as joint infection and cartilage degradation, factors that often discourage sustained clinical application. Consequently, healthcare providers are compelled to restrict the frequency of usage, which poses a notable challenge to the consistent growth of the injection therapy sector.

Market Driver

The rising incidence of rheumatoid arthritis and osteoarthritis serves as the primary engine for the Global Joint Pain Injections Market. As the worldwide population ages, the burden of degenerative joint conditions increases, generating a steady demand for non-surgical symptom relief. This demographic shift forces healthcare systems to prioritize injectable therapies, such as hyaluronic acid and corticosteroids, to manage pain and postpone invasive procedures like total knee arthroplasty. A June 2025 report from the Centers for Disease Control and Prevention, titled 'Preventing Chronic Disease', noted that the crude prevalence of diagnosed arthritis among U.S. adults aged 20 and older reached 27.9%, underscoring the vital need for effective intra-articular treatments to support workforce productivity and quality of life.

Additionally, surging global obesity rates are accelerating joint degeneration and propelling market expansion by lowering the average age of arthritis onset. Excess body weight places severe mechanical stress on weight-bearing joints, hastening cartilage breakdown and necessitating earlier therapeutic intervention. In March 2025, the World Obesity Federation's 'World Obesity Atlas 2025' projected that the number of adults living with obesity globally would rise to 1.13 billion by 2030. This trend correlates with increased musculoskeletal comorbidities, prompting pharmaceutical developers to broaden their pain management portfolios. Reflecting this, Anika Therapeutics reported in 2025 that revenue for its international osteoarthritis pain management products grew by 17% in 2024 compared to the previous year.

Market Challenge

The principal hurdle restraining the growth of the global joint pain injections market is the safety concern surrounding the prolonged use of intra-articular corticosteroids. Although these agents offer effective temporary relief, their sustained administration is limited by risks such as cartilage degradation and joint infections. As a result, healthcare professionals are forced to cap the frequency of treatments, often restricting patients to a specific quota of injections per year. This safety ceiling prevents the therapy from becoming a continuous solution for chronic pain management, thereby limiting revenue volume per patient and reducing overall market penetration compared to oral analgesics, which can be taken daily without similar procedural constraints.

This restriction is particularly significant given the vast patient population requiring consistent pain management. According to the Centers for Disease Control and Prevention, 21.3% of adults in the United States had diagnosed arthritis in 2025. This statistic highlights a massive demographic seeking relief; however, the inability to safely administer corticosteroid injections frequently creates a major bottleneck in service delivery. The disparity between the high prevalence of the condition and the restricted usage frequency of the treatment directly hampers the market's ability to fully capitalize on the demand for effective musculoskeletal therapies.

Market Trends

The market is being reshaped by the adoption of orthobiologics and regenerative medicine, as clinicians increasingly prioritize tissue repair over temporary symptom management. This trend involves integrating biologic solutions, such as platelet-rich plasma and hyaluronic acid-based scaffolds, which are designed to restore damaged cartilage and delay joint replacement surgeries. Healthcare providers are swiftly incorporating these therapies into treatment protocols to address the root causes of joint degeneration rather than merely masking pain. In its 'Third Quarter 2025 Financial Results' from November 2025, Anika Therapeutics reported a 25% revenue increase in its Regenerative Solutions segment, driven largely by the market success of the Integrity Implant System and strong international adoption of Hyalofast.

A concurrent shift toward single-injection viscosupplementation regimens is gaining traction due to the demand for reduced clinical burden and greater patient convenience. Unlike traditional multi-injection courses that require repeated hospital visits, single-injection high-molecular-weight hyaluronic acid formulations provide sustained therapeutic benefits in a unified administration. This approach improves operational efficiency for medical practices and enhances patient compliance, making it a preferred option for managing knee osteoarthritis. According to Bioventus's November 2025 'Third Quarter Financial Results', global revenue for its Pain Treatments segment accelerated by 6.4%, primarily fueled by robust U.S. demand for Durolane, a differentiated single-injection hyaluronic acid therapy.

Key Market Players

• Anika Therapeutics Inc
• Bioventus LLC
• Ferring Pharmaceuticals Inc
• Sanofi SA
• Pfizer Inc
• Eli Lilly & Co
• Flexion Therapeutics Inc
• Teva Pharmaceutical Industries Ltd
• Zimmer Biomet Holdings, Inc.

Report Scope

In this report, the Global Joint Pain Injections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Joint Pain Injections Market, By Type of Injection

• Steroid Joint Injections
• Hyaluronic Acid Injections
• Platelet-rich Plasma (PRP) Injections
• Placental Tissue Matrix (PTM) Injections
• Others

Joint Pain Injections Market, By Application

• Shoulder & Elbow
• Knee & Ankle
• Spinal Joints
• Hip Joint
• Others

Joint Pain Injections Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Joint Pain Injections Market.

Available Customizations:

Global Joint Pain Injections Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Joint Pain Injections Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections, Others)
  • 5.2.2. By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Joint Pain Injections Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Injection
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Joint Pain Injections Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Injection
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Joint Pain Injections Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Injection
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Joint Pain Injections Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Injection
      • 6.3.3.2.2. By Application

7. Europe Joint Pain Injections Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Injection
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Joint Pain Injections Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Injection
      • 7.3.1.2.2. By Application
  • 7.3.2. France Joint Pain Injections Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Injection
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Joint Pain Injections Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Injection
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Joint Pain Injections Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Injection
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Joint Pain Injections Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Injection
      • 7.3.5.2.2. By Application

8. Asia Pacific Joint Pain Injections Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Injection
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Joint Pain Injections Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Injection
      • 8.3.1.2.2. By Application
  • 8.3.2. India Joint Pain Injections Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Injection
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Joint Pain Injections Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Injection
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Joint Pain Injections Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Injection
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Joint Pain Injections Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Injection
      • 8.3.5.2.2. By Application

9. Middle East & Africa Joint Pain Injections Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Injection
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Joint Pain Injections Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Injection
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Joint Pain Injections Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Injection
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Joint Pain Injections Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Injection
      • 9.3.3.2.2. By Application

10. South America Joint Pain Injections Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Injection
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Joint Pain Injections Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Injection
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Joint Pain Injections Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Injection
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Joint Pain Injections Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Injection
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Joint Pain Injections Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Anika Therapeutics Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bioventus LLC
• 15.3. Ferring Pharmaceuticals Inc
• 15.4. Sanofi SA
• 15.5. Pfizer Inc
• 15.6. Eli Lilly & Co
• 15.7. Flexion Therapeutics Inc
• 15.8. Teva Pharmaceutical Industries Ltd
• 15.9. Zimmer Biomet Holdings, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer